Key facts
- TearSolutions’s last known valuation is $280.0M (Nov 2024).
- It has raised $44.1M across 11 recorded rounds; the latest was Seed Round ($517K) in Oct 2025.
- Notable investors include Virginia Innovation Partnership Corporation, Virginia Venture Partners, CAV Angels, University of Virginia, Dave Metzak — 13 tracked in total.
- TearSolutions has filed 13 Form Ds with the SEC since 2014, most recently Oct 2024 ($12.7M sold to 80 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 11 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for TearSolutions
Funding rounds
11 roundsAbout TearSolutions
Developer of a peptide therapy designed for the treatment of signs and symptoms of dry eye in primary sjögren's syndrome patients. The company's product helps patient preserves all of the biological activity of a naturally occurring tear protein by introducing a short stable peptide that can be produced at scale and restore basal tearing without irritation and heal the corneal surface of the eye, providing patients with rapid improvement in corneal health and a reduction in symptoms of dry eyes.
- Sector
- Healthcare
- HQ
- Charlottesville, VA, United States
- Founded
- 2013
- Employees
- 10
- Website
- tearsolutions.com/
- Ownership
- Privately Held (backing)
TearSolutions doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TearSolutions shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TearSolutions in its N-PORT filings yet. We sweep new filings monthly.